WO2007016153A3 - Formulation de tilmicosine - Google Patents

Formulation de tilmicosine Download PDF

Info

Publication number
WO2007016153A3
WO2007016153A3 PCT/US2006/029000 US2006029000W WO2007016153A3 WO 2007016153 A3 WO2007016153 A3 WO 2007016153A3 US 2006029000 W US2006029000 W US 2006029000W WO 2007016153 A3 WO2007016153 A3 WO 2007016153A3
Authority
WO
WIPO (PCT)
Prior art keywords
tilmicosin
formulation
tilmicosin formulation
same
calcium
Prior art date
Application number
PCT/US2006/029000
Other languages
English (en)
Other versions
WO2007016153A2 (fr
Inventor
Paul Reuben Klink
Robin Shane Readnour
Original Assignee
Lilly Co Eli
Paul Reuben Klink
Robin Shane Readnour
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Paul Reuben Klink, Robin Shane Readnour filed Critical Lilly Co Eli
Publication of WO2007016153A2 publication Critical patent/WO2007016153A2/fr
Publication of WO2007016153A3 publication Critical patent/WO2007016153A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation injectable comprenant de la tilmicosine, du calcium, et un véhicule liquide, des méthodes d'utilisation de cette formulation, et des procédés de préparation de cette formulation.
PCT/US2006/029000 2005-07-28 2006-07-26 Formulation de tilmicosine WO2007016153A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70313905P 2005-07-28 2005-07-28
US60/703,139 2005-07-28
US75632406P 2006-01-05 2006-01-05
US60/756,324 2006-01-05

Publications (2)

Publication Number Publication Date
WO2007016153A2 WO2007016153A2 (fr) 2007-02-08
WO2007016153A3 true WO2007016153A3 (fr) 2007-04-19

Family

ID=37671225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/029000 WO2007016153A2 (fr) 2005-07-28 2006-07-26 Formulation de tilmicosine

Country Status (1)

Country Link
WO (1) WO2007016153A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143319B2 (en) 2006-07-18 2012-03-27 The Regents Of The University Of California Method and apparatus for steam hydro-gasification with increased conversion times
CN104906039B (zh) * 2015-06-29 2018-07-03 湖南泰谷生物科技股份有限公司 一种替米考星注射用混悬剂及其制备方法
CN109464413A (zh) * 2018-12-04 2019-03-15 中牧实业股份有限公司黄冈动物药品厂 一种替米考星微丸及其制备方法
CN114796108B (zh) * 2022-06-30 2022-09-02 山东国邦药业有限公司 一种替米考星溶液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130211A1 (en) * 2001-10-19 2003-07-10 Murthy Yerramilli V.S.N. Injectable compositions for the controlled delivery of pharmacologically active compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130211A1 (en) * 2001-10-19 2003-07-10 Murthy Yerramilli V.S.N. Injectable compositions for the controlled delivery of pharmacologically active compound

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2000 (2000-11-01), SAKURAI HARUHIKO ET AL: "Cardiogenic shock triggered by verapamil and atenolol: A case report of therapeutic experience with intravenous calcium", XP002419159, Database accession no. PREV200000543182 *
HACK J B ET AL: "Pilot study: Use of calcium chloride to treat hyperkalemia due to acute digoxin toxicity in a swine model.", JOURNAL OF TOXICOLOGY CLINICAL TOXICOLOGY, vol. 41, no. 5, August 2003 (2003-08-01), & ANNUAL MEETING OF THE NORTH AMERICAN CONGRESS OF CLINICAL TOXICOLOGY; CHICAGO, IL, USA; SEPTEMBER 04-09, 2003, pages 696, XP009078256, ISSN: 0731-3810 *
PORTER J M ET AL: "The efficacy of nicorandil, calcium chloride and nitroglycerin in treatment of ropivacaine-induced cardiotoxicity.", EUROPEAN JOURNAL OF ANAESTHESIOLOGY, vol. 20, no. 12, December 2003 (2003-12-01), pages 939 - 944, XP009078234, ISSN: 0265-0215 *

Also Published As

Publication number Publication date
WO2007016153A2 (fr) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2006116348A3 (fr) Compositions destinees a des dispositifs medicaux contenant des combinaisons d'agents dans des volumes controles
WO2008070269A3 (fr) Procédés, logiciel et systèmes d'imagerie
WO2007133290A8 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2007130697A8 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2008060705A8 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2009152276A3 (fr) Générateurs de photoacides et résists lithographiques les comprenant
IL184175A (en) Sulfonyl pyrrolidines, method for producing the same and their use as drugs
EP1733932B8 (fr) Airbag, procédé de fabrication celui-ci, dispositif d'airbag et véhicule
WO2007076062A3 (fr) Formulations de proteines a viscosite reduite et leurs utilisations
PL1954745T3 (pl) Preparat środka zwiększającego przyczepność, sposób jego wytwarzania oraz jego zastosowanie
WO2007076132A3 (fr) Compositions comprenant des macromolecules immobilisees et orientees et leurs procedes de preparation
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
EP1885883A4 (fr) Biodisque, appareil de biolecteur et procede d'essai faisant appel a ceux-ci
WO2007047781A3 (fr) Gels hydrophobes reticules pour revetements bioabsorbables de vecteur de medicament
WO2009058379A3 (fr) Structures protéiques
WO2008054676A3 (fr) Dispositifs médicaux et méthodes d'utilisation correspondantes
WO2010077898A3 (fr) Trans-chloro-3,3,3-trifluoropropène destiné à être utilisé dans des applications de refroidisseurs
WO2007067469A3 (fr) Procédé permettant d'expulser un gaz positionné entre un substrat et un moule
WO2006124713A3 (fr) 4-biarylyl-1-phenylazetidin-2-ones
WO2006083936A3 (fr) Anticorps anti-ephb2 et methodes d'utilisation associees
WO2007076174A3 (fr) Procédés, systèmes et dispositif pour marqueurs multidomaines
WO2007127506A3 (fr) Anticorps anti-ephrinb2 et procédés les utilisant
WO2007075870A3 (fr) Procedes pour derives de taxane et intermediaires utiles correspondants
WO2005074645A3 (fr) Procedes et compositions permettant de moduler l'angiogenese
WO2006098998A3 (fr) Procedes et compositions de modulation de l'integrite vasculaire

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06788537

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06788537

Country of ref document: EP

Kind code of ref document: A2